 |
Previous Article | Next Article 
The Journal of Neuroscience, September 1, 2001, 21(17):6846-6852
Pharmacological Modulation of Behavioral and Neuronal Correlates
of Repetition Priming
Christiane M.
Thiel1,
Richard N. A.
Henson1, 2,
John S.
Morris1,
Karl J.
Friston1, and
Raymond J.
Dolan1, 3
1 Wellcome Department of Cognitive Neurology, Institute
of Neurology, London, WC1 3BG, United Kingdom, 2 Institute
of Cognitive Neuroscience, University College London, London WC1 3BG,
United Kingdom, and 3 Royal Free Hospital School of
Medicine, London NW3 2PF, United Kingdom
 |
ABSTRACT |
In this experiment we address the pharmacological modulation of
repetition priming, a basic form of learning, using event-related functional magnetic resonance imaging. We measured brain
activity in a word-stem completion paradigm in which, before study,
volunteers were given either placebo, lorazepam (2 mg orally), or
scopolamine (0.4 mg, i.v.). Relative to placebo, both drugs attenuated
the behavioral expression of priming. Repetition was associated with a
decreased neuronal response in left extrastriate, left middle frontal,
and left inferior frontal cortices in the placebo group. Both drugs
abolished these "repetition suppression" effects. By showing a
concurrence of behavioral and neuronal modulations, the results suggest
that GABAergic and cholinergic systems influence the neuronal
plasticity necessary for repetition priming.
Key words:
fMRI; priming; scopolamine; lorazepam; psychopharmacology; neuroimaging; word-stem completion; repetition
suppression
 |
INTRODUCTION |
Previous exposure to a stimulus
facilitates or biases its subsequent processing. This behavioral
phenomenon is known as repetition priming and is likely to constitute a
basic learning mechanism (Wiggs and Martin, 1998 ; Schacter and Buckner,
1998 ). One possible neuronal signature for this form of learning is
"response suppression," a decrement in the response to repeated
stimuli in neurons that fire to initial presentations (Desimone, 1996 ).
In monkeys, for example, a subpopulation of cells in inferior temporal
cortex shows reduced neuronal firing when novel stimuli are repeated (Li et al., 1993 ). In humans, analogous decreases in hemodynamic response after repetition in brain areas such as extrastriate and
frontal cortices have been demonstrated with neuroimaging methods
(Squire et al., 1992 ; Buckner et al., 1998 , 2000 ; Wagner et al.,
2000 ).
Cholinergic mechanisms exert a regulatory function with respect to the
expression of plasticity (Brocher et al., 1992 ; Weinberger, 1998 ;
Rasmusson, 2000 ) and learning (Blokland, 1996 ). Although cholinergic
modulation of learning, and corresponding neuronal activity, has been
shown in many explicit learning paradigms (Caine et al., 1981 ; Frith et
al., 1984 ; Nissen et al., 1987 ; Rusted and Warburton, 1988 ; Curran et
al., 1991a ; Furey et al., 2000 ), its effects on behavioral measures in
implicit paradigms is more controversial. Psychopharmacological and
electrophysiological evidence suggests an absence of cholinergic
modulation on repetition priming, because several studies found no
behavioral (Danion et al., 1990 ; Knopman, 1991 ; Schifano and Curran,
1994 ) or neuronal (Miller and Desimone, 1993 ) modulation of repetition
effects after administration of the cholinergic antagonist scopolamine.
By contrast, manipulations of GABAergic neurotransmitter systems with
the benzodiazepine lorazepam impairs behavioral indices of repetition
priming in humans (Knopman, 1991 ; Buffett-Jerrott et al., 1998 ;
Vidailhet et al., 1999 ).
In this study, we address the pharmacological modulation of repetition
priming at both the behavioral and neuronal levels. We combined
event-related functional magnetic resonance imaging (fMRI) with drug
challenge in a word-stem completion paradigm in which the behavioral
index of priming was a bias in the completions of word-stems in favor
of previously presented words. Results from previous neuroimaging
studies, using word-stem completion, enabled specific predictions of
repetition suppression in left extrastriate, left inferior, and middle
frontal cortex (Buckner et al., 2000 ). Thus, the experimental question
of interest was whether lorazepam and scopolamine would modulate
repetition suppression in these regions.
 |
MATERIALS AND METHODS |
Subjects. Forty-seven right-handed native
English-speaking participants (29 male, 18 female; age range, 18-37
years) with no history of medical or psychiatric disease gave informed
consent to participate in the study. We excluded 10 participants from analysis. Exclusion criteria were technical failure (n = 2), excessive head movement (n = 2), or <60% of
word stems completed (n = 6). The effective group size
was n = 13 for placebo (8 male, 5 female; mean age,
23.92 ± 1.22), n = 12 for lorazepam (9 male, 3 female; mean age, 23.00 ± 1.37), and n = 12 for
scopolamine (6 male, 6 female; mean age, 24.08 ± 1.34).
Drugs. A double-blind, double-dummy, time-elapsed drug
administration technique was used, so that each subject received a tablet orally and an injection intravenously 120 and 80 min,
respectively, before the start of the study phase, i.e., (1) placebo
orally plus saline intravenously, (2) 2 mg of lorazepam orally plus
saline intravenously, or (3) placebo orally plus 0.4 mg of scopolamine intravenously. Drug doses and administration schedule were chosen according to the literature to induce behavioral impairments. Doses
between 2 and 3 mg of oral lorazepam have been shown to reliably impair
repetition priming, whereas lower doses are less effective (Knopman,
1991 ; Legrand et al., 1995 ; Buffett-Jerrott et al., 1998 ). Maximal
effects occur at 2 hr after ingestion, which also corresponds to peak
plasma levels (Legrand et al., 1995 ). Scopolamine was administered
intravenously because oral scopolamine has variable absorption, poor
bioavailability, and is behaviorally less effective (Nuotto, 1983 ;
Putcha et al., 1989 ). The dose of scopolamine was chosen because
intravenous injections in this dose range have been reported to affect
a variety of cognitive functions (Sunderland et al., 1987 ; Martinez et
al., 1997 ; Vitiello et al., 1997 ). Scopolamine was administered 80 min
before scanning, because previous studies have shown that cognitive
effects of intravenous scopolamine peak from 90 to 150 min after
administration (Safer and Allen, 1971 ; Sannita et al., 1987 ; Curran et
al., 1991b ; Ebert et al., 1998 ).
Experimental paradigm. Stimuli were selected from a pool of
200 target words so that the initial three letters were unique and
could be completed by at least six English words (Badgaiyan et al.,
1999 ). Stimuli were randomly divided into two sets of 100 words, A and
B. Set A was used during scanning to index priming-related brain
activity, whereas set B was used after scanning to obtain a behavioral
measure of priming. Both sets were divided again into two subsets.
During the prescanning study phase, all words of one or the other of
the subsets of list A were displayed every 5 sec for 5 sec on a
Macintosh computer, and subjects were asked to read the words aloud and
rate them by pleasantness. At test, participants were presented with a
completion task for the 50 stems of the words presented in the study
phase ("old word-stems") randomly intermixed with stems of
nonpresented words ("new word-stems"). The assignment of subsets to
old or new items was counterbalanced across subjects, so that
completions for the new stems in one subject acted as the baseline for
another in which that subset comprised the old items. Stimuli
[including 50 "null events" (Josephs and Henson, 1999 )] were
displayed every 4 sec for 1 sec against a baseline of fixation crosses
on a Macintosh computer, projected onto a screen ~300 mm above the
subject in the magnetic resonance imaging (MRI) scanner. Participants
were asked to complete the stems covertly with the first word that came
to mind and make a right index finger key press for every completion.
For postscanning word-stem completion, participants were presented with
words of one or other of the subsets of list B and asked to read the
words aloud. One half of those words was rated by pleasantness, and the
other half was counted for the presence of letters with enclosed spaces
(e.g., an "a" contains an enclosed space, but an "r" does not).
The aim of processing half the words in the study phase "deeply"
(rating by "liking") opposed to "shallowly" (counting enclosed
spaces) was to determine the contribution of explicit memory processes
to task performance (Graf and Mandler, 1984 ). During the test phase,
completion of word stems was overt. The comparison of completions of
old word-stems with previously presented words and new word-stems with
words from the nonpresented subset provided a behavioral index of
repetition priming. Behavioral data were analyzed with a three × two-way ANOVA for repeated measures with drug as a between-subject
factor and priming (new vs old word-stems) as a within-subject factor.
Significant effects were followed by post hoc Tukey tests
comparing priming between and within groups.
Imaging and image processing. A VISION MRI system (Siemens,
Erlangen, Germany) operating at 2 T was used to obtain T2*-weighted echoplanar (EPI) images (64 × 64, 3 × 3 mm pixels) with
blood oxygenation level-dependent (BOLD) contrast. Two hundred and
fifty volumes of 30 2-mm-thick axial slices were acquired sequentially every 3.5 mm (repetition time, 2.5 sec; echo time, 40 msec). The first
five volumes were discarded to allow for T1 equilibration effects.
Images were realigned to correct for interscan movement, synchronized
to the middle slice to correct for differences in slice acquisition
time, and normalized to a standard EPI template volume. The data were
then smoothed with a Gaussian kernel of 8 mm full-width half-maximum to
accommodate intersubject anatomical variability.
Statistical analysis of images. Data were analyzed with
statistical parametric mapping software (SPM99; Wellcome Department of
Cognitive Neurology, London, UK; Friston et al., 1995 ) using a
random effects analysis. Data were globally scaled to 100 across scans
and highpass-filtered at 1/60 Hz. The hemodynamic response to stimulus
onset for each event type was modeled by a canonical synthetic
hemodynamic response function (HRF) and its first-order temporal
derivative. Three event types were modeled (new and old words as
effects of interest and missed responses as effect of no interest). The
six head movement parameters were included as confounds. Linear
contrasts of parameter estimates for the canonical HRF for each subject
were taken to a second level analysis to generate statistical
parametric maps (SPMs) of the t-statistic. An SPM
(thresholded at p < 0.001, uncorrected) of voxels
showing significant responses during task performance (i.e., main
effect) was created and used as a mask to identify brain regions
showing repetition suppression and group by repetition interactions.
Additionally, percentage of signal change for the effect maxima in the
three regions of interest (left extrastriate, left middle frontal, and left inferior frontal cortices), showing a drug by repetition interaction, were plotted for each group. These data were analyzed in
the same way as the behavioral data, i.e., with a three × two-way ANOVA for repeated measures followed by post hoc Tukey's tests.
 |
RESULTS |
Subjects were randomly allocated to three groups and given either
placebo, lorazepam (2 mg oral), or scopolamine (0.4 mg, i.v.). In a
study phase, conducted outside the scanner, and after drug or placebo
administration, subjects were presented visually with a list of words
and asked to read them aloud and rate them for pleasantness. Scanning
took place during a subsequent test phase, during which subjects
performed a completion task in relation to three-letter stems of words
presented at study (old word-stems) randomly intermixed with stems of
nonpresented words (new word-stems) (Fig.
1). To minimize response-related head
movement, participants were asked to complete stems covertly with the
first word that came to mind and make a right index finger key press
after every completion. Covert word-stem completion has been found to
yield similar repetition priming effects to overt word-stem completion (Buckner et al., 2000 ). Immediately after scanning, the task was repeated with a new set of stimuli and overt stem completion to obtain
a behavioral measure of priming.

View larger version (23K):
[in this window]
[in a new window]
|
Figure 1.
Experimental paradigm. Illustration of stimuli
presented during study and test phases. Test stimuli were either
word-stems that could be completed with words presented in the study
phase (old) or stems that could not
(new). Stimuli were randomly displayed every 4 sec for 1 sec against a baseline of fixation crosses.
|
|
Analysis of behavioral data with a three × two-way ANOVA for
repeated measures yielded a drug by repetition interaction
(F(2,34) = 6.32; p = 0.005) (Fig. 2). Relative to placebo,
priming was significantly attenuated, although not abolished, in both
drug groups (post hoc Tukey tests old word-stems in
drug groups vs old word-stems in placebo group, p < 0.05; post hoc Tukey tests new word-stems vs old word-stems
in the lorazepam and scopolamine group, p < 0.05).
This indicates that repetition priming in word-stem completion
paradigms is sensitive to both cholinergic and GABAergic drug
manipulation.

View larger version (24K):
[in this window]
[in a new window]
|
Figure 2.
Behavioral performance in word-stem completion
paradigm. Mean and SEM of word-stems completed with target words from
the previously presented list (old; subdivided into deep and shallow)
and words from previously nonpresented list (new = chance
completion). Note that, for purposes of illustration in deep and
shallow conditions, percentages refer to percentage of stems completed
from the whole previously presented list (irrespective of how words
were encoded i.e., the maximum value in both conditions would be
50%). Data were analyzed with ANOVAs for repeated measures, with drugs
as a between-subject factor and priming (new vs old stems) as a
within-subject factor. Significant effects were followed by post
hoc Tukey's tests comparing placebo and drug groups
(*p < 0.05; ***p < 0.001).
|
|
To determine whether sedation contributed to these effects, we (1)
compared the total number of completed word-stems (old and new) in
placebo and drug groups and (2) correlated subjective sedation with the
behavioral index of repetition priming. Subjective sedation was
assessed with visual analog scales (Bond and Lader, 1974 ). There was
neither a group difference in total number of completed word-stems
(F(2,34) = 1.101; p = 0.344) nor a correlation between measures of sedation and priming
(r = 0.111; p = 0.514). A second
concern was that attenuation of repetition priming might reflect the
action of lorazepam and scopolamine on explicit memory. As described
(see Materials and Methods), we included a deep and shallow encoding
condition in the postscanning word-stem completion (Graf and Mandler,
1984 ). The absence of a difference in priming after deep or shallow
encoding (F(1,34) = 0.354;
p = 0.556) suggests that priming effects were mediated
primarily by implicit memory processes. Consequently, it is unlikely
that drug effects reflect an impairment of explicit memory processes.
To illustrate the overall task effect in all three groups brain regions
showing activity during word-stem completion compared with fixation are
shown in Figure 3. A network of regions
were activated in all groups, including bilateral extrastriate regions, left frontal regions along the inferior frontal gyrus, the anterior cingulate, and the bilateral cerebellar cortex, confirming results from
previous fMRI studies (Buckner et al. 2000 ). Furthermore, these
findings are in line with our behavioral data, showing that task
performance (i.e., the number of completed word-stems) was not
different between groups.

View larger version (71K):
[in this window]
[in a new window]
|
Figure 3.
Regions showing activations during word-stem
completion (new and old word-stems) against fixation, as identified by
random effects analysis in the placebo, lorazepam, and scopolamine
groups, respectively. Activations are rendered on transverse mean
normalized EPI images (EPI images averaged over several volunteers;
threshold = p < 0.001). EPI images are used
for anatomical descriptions, because they show the same distortions as
activation data. A pathway of regions is activated, including bilateral
extrastriate regions, left frontal regions along the inferior frontal
gyrus, the anterior cingulate, and bilateral cerebellar cortex. The
left lateral parietal cortex and precentral gyrus were only
significantly activated in the placebo group.
|
|
Because both drugs impaired the behavioral expression of repetition
priming, our main question was whether these effects are expressed in a
modulation of the neuronal index of repetition suppression. This
question was addressed in two planned comparisons. First, we identified
brain regions showing significant repetition suppression under placebo.
Second, we compared the magnitude of these reductions by contrasting
the placebo and drug groups (averaging across scopolamine and
lorazepam), i.e., we tested for a group (placebo and drug) by
repetition interaction. In the placebo group (Fig.
4a), repetition-related
decreases were evident in several brain areas, including left
extrastriate cortex, left inferior frontal cortex, and left middle
frontal cortex, regions previously shown to manifest repetition
suppression effects (Buckner et al., 2000 ). A comparison of
repetition-related effects in placebo and the combined drug groups
revealed a significant interaction in these same regions, including
left extrastriate, left middle frontal, and to a lesser extent, left
inferior frontal cortex (Fig. 4b). This drug-by-repetition
interaction reflected an absence of repetition suppression after
lorazepam and scopolamine. In other words, repetition suppression was
impaired in the presence of the two pharmacological agents.
Consequently, GABAergic and cholinergic influences on repetition
priming in word-stem completion paradigms are expressed as an
attenuation of repetition suppression in the same brain areas
associated with repetition effects in the placebo group and in previous
studies using this paradigm (Buckner et al., 2000 ).

View larger version (64K):
[in this window]
[in a new window]
|
Figure 4.
Regions showing repetition suppression, as
identified by random effects analysis. Activations (thresholded at
p < 0.01 for purposes of illustration) are
rendered on transverse mean normalized EPI images. A,
Regions showing repetition-related activation reductions [(placebo
new-old), i.e., increased activity for new compared with old
word-stems] in the placebo group. Regions highlighted
by circles are: left inferior frontal cortex ( 48, 39, 6; Z = 3.22), left extrastriate cortex ( 36,
81, 6; Z = 3.14), and left middle frontal
cortex ( 30, 0, 57; Z = 3.67). Other areas
activated at p < 0.001 include: cerebellum (0, 78, 24, Z = 4.67 and 21, 60, 24,
Z = 3.98), left thalamus ( 9, 9, 3;
Z = 3.63), left cingulate ( 12, 18, 36;
Z = 3.64), right caudate (18, 6, 18;
Z = 3.56), right extrastriate (39, 66, 30;
Z = 3.39), and right inferior frontal cortex (30, 27, 9; Z = 3.26). B, Regions
showing a repetition by drug interaction [i.e., (placebo new-old) - (drug new-old)]. Regions highlighted are: left inferior frontal
cortex ( 45, 39, 9; Z = 3.06), left extrastriate
cortex ( 36, 75, 6; Z = 3.73), and left middle
frontal cortex ( 39, 3, 54; Z = 3.67). Further
areas activated at p < 0.001 include: right
cerebellum (9, 75, 24; Z = 3.7), left cingulate
( 12, 15, 36; Z = 3.51), left thalamus ( 9, 9, 3;
Z = 3.24), and left inferior parietal cortex ( 30,
51, 48; Z = 3.08). In all these regions both
drugs lead to a significant decrease in repetition suppression compared
with placebo. When we used regions showing repetition suppression in
the placebo group as a mask within which to identify a group × repetition interaction several areas survived a small volume correction
based on this search volume. These included: left extrastriate cortex
(p = 0.015, corrected), left middle frontal
cortex (p = 0.021, corrected), cingulate
(p = 0.023, corrected), and cerebellum
(p = 0.012, corrected).
|
|
One possible issue of concern in a drug study is that of sedation. To
determine whether sedation contributed to these neuronal effects, we
correlated subjective sedation with the neuronal index of repetition
priming. There was no correlation between measures of sedation and
repetition suppression in left extrastriate (r = 0.20; p = 0.235), left middle frontal
(r = 0.036; p = 0.831), and left
inferior frontal cortex (r = 0.121; p = 0.477). An additional concern is the possibility of drug effects on
global perfusion, consequently to investigate whether the drugs might
have interfered with global cerebral blood flow (gCBF), we compared the
estimated global BOLD signal across the brain between the drug groups.
No differences in this global estimate were found (ANOVA,
F(2,34) = 0.406; p = 0.669).
A further exploration of the data were performed to evaluate (1) the
contribution of lorazepam and scopolamine to the drug by repetition
interaction and (2) the mechanisms underlying the absence of repetition
suppression. Theoretically an absence of repetition suppression might
be driven by an increased responses to old word-stems in the drug
groups relative to responses to old word-stems in the placebo group or
decreased responses to new word-stems in the drug groups relative to
responses to new word-stems in the placebo group. In Figure
5A-C we plot the percentage of signal change for the effect maxima separately for the three drug
groups. A statistical analysis identical to that for behavioral data
(i.e., three × two-way ANOVA for repeated measures followed by
post hoc Tukey tests) showed that both drugs
interfered with repetition suppression in left extrastriate (ANOVA drug
by repetition interaction, F(2,34) = 7.595, p = 0.002), left middle frontal (ANOVA drug by
repetition interaction, F(2,34) = 7.772, p = 0.002), and left inferior frontal cortex
(ANOVA drug by repetition interaction, F(2,34) = 6.109; p = 0.005).

View larger version (33K):
[in this window]
[in a new window]
|
Figure 5.
Plots of percentage of signal change. Mean and SEM
as a function of group and repetition (new stems, black
symbols; old stems, white symbols). The plots in
A-C derive from the maximum voxel in each region
identified by random effects analysis. D shows a voxel
in primary visual cortex. The placebo group shows repetition
suppression in left extrastriate, left inferior frontal, and left
middle frontal cortices. There is an absence of repetition-related
reductions in all three brain areas after lorazepam and scopolamine.
Compared with placebo, lorazepam reduced activations to new words in
all three brain regions. In contrast, scopolamine showed increased
activations to old words compared with placebo in extrastriate cortex.
Note that the voxel in primary visual cortex shows neither repetition
suppression nor an effect of drug. **p < 0.05;
***p < 0.001; ANOVAs followed by post
hoc Tukey's tests comparing activations to new and old words
between placebo and drug groups.
|
|
Differences were apparent in the nature of the interference with
repetition suppression, i.e., different modulation of neuronal responses to old or new items by lorazepam and scopolamine when compared with placebo. For lorazepam, the interference with repetition suppression was driven primarily by reduced activation to new word-stems in left extrastriate and frontal cortex (Tukey tests against
placebo, p < 0.05). Scopolamine, on the other hand,
interfered with repetition suppression in left extrastriate cortex by
significantly increasing responses to old word-stems with respect to
placebo (Tukey tests against placebo, p < 0.05), while
leaving responses to new word-stems intact. Intact responses to new
word-stems were also seen in inferior frontal cortex. To determine
whether these patterns of impaired repetition priming were
significantly different between lorazepam and scopolamine, we directly
compared the two drug groups using a two × two-way ANOVA for
repeated measures. We found a significant drug effect in extrastriate
cortex showing greater activation under scopolamine compared with
lorazepam (ANOVA main effect drug,
F(1,22) = 8.797, p = 0.007). No significant drug effects or drug by repetition interactions
were found for other brain regions (ANOVAs, p > 0.05).
To determine whether the drugs nonspecifically interfered with brain
activity during task performance, results from a voxel in primary
visual cortex (12, 90, 6), which showed stimulus-driven responses during word-stem completion, were plotted (Fig.
5D). If the action of lorazepam or scopolamine was
nonspecific, drug-related modulations would be expected in this primary
visual brain area. No group (ANOVA,
F(2,34) = 0.069, p = 0.933), or group by repetition interaction (ANOVA,
F(2,34) = 0.481, p = 0.622) was evident in primary visual cortex, indicating that the drugs
did not modulate activity in primary visual areas.
 |
DISCUSSION |
Our behavioral findings indicate that both lorazepam and
scopolamine influence the behavioral expression of word-stem completion priming, whereas neuroimaging data provide evidence that this same
modulation impairs repetition suppression. The findings thus provide
evidence for specific neuronal events associated with drug-attenuated
repetition priming during word-stem completion.
An important theoretical consideration is the possibility that drugs,
such as scopolamine, might affect gCBF and/or regional cerebral blood
flow (rCBF). Tsukada et al. (1997) have shown in monkeys that rCBF to
somatosensory stimulation is abolished by scopolamine. The doses shown
to yield this effect were however 10 times higher than the dose used
here, and of critical relevance is the fact that no effects on rCBF
were found at a lower dose. To account for possible differences in gCBF
between the groups in our data, global scaling was used in the data
analysis. Furthermore, we found no evidence for a difference when we
compared the estimated global BOLD signal between the drug groups,
which makes significant changes in gCBF unlikely. Another concern might
be fluctuation in drug effects over the time course of the experiment.
In relation to the half-life of lorazepam (8-25 hr) (Greenblatt,
1981 ), only minor fluctuations can be expected during the course of the
experiment. The half-life of scopolamine (220 min) is a potentially
greater concern, and a decline in drug levels might occur between
scanning and behavioral testing. However, because we found robust
behavioral effects after scanning, we can, at a minimum, be confident
that the drug was still centrally active. Additionally a study
investigating the cerebral distribution kinetics of radioactively
labeled scopolamine showed only minor changes in cortical scopolamine
concentration between 60 and 120 min after injection, with
still-increasing activity at the latter time point (Frey et al., 1992 ).
On this basis we can infer that drug fluctuations between imaging and postscanning behavioral measures are negligible.
The attenuation of behavioral indices of repetition priming with
lorazepam is consistent with previous psychopharmacological studies
(Buffett-Jerrott et al., 1998 ; Vidailhet et al., 1999 ). In contrast to
most previous studies, however (Danion et al., 1990 ; Knopman, 1991 ;
Schifano and Curran, 1994 ), our results with scopolamine also
demonstrate a cholinergic modulation of repetition priming. We suggest
that these differences could be attributable to a lower active dose
used in these previous studies (subcutaneous or intramuscular
injections are centrally less effective) so that priming was not
significantly impaired. Indeed the study by Schifano and Curran (1994) ,
which used two doses of scopolamine, found a tendency toward attenuated
repetition priming at higher doses of the drug.
A lack of repetition suppression after lorazepam and scopolamine was
found in those brain areas associated with repetition effects in the
placebo group, suggesting that GABAergic and cholinergic systems
influence repetition priming through modulation of neuronal plasticity
in these brain areas. We do not have an explanation why the remaining
priming effect in the drug groups co-occurred with a lack of repetition
suppression, it might however simply reflect a lack of power to pick up
repetition suppression with low levels of priming.
The disruption of repetition suppression with scopolamine might seem
inconsistent with electrophysiological data of Miller and Desimone
(1993) where no effect on repetition suppression was evident. Important
methodological differences in these studies are likely to account for
these apparent discrepancies. First, the recording sites in the former
study were more anterior than activations we report in extrastriate
cortex. Second, the time interval between first and second presentation
of the stimuli was different. In Miller and Desimone (1993) , the first
and second presentation of the stimuli was less than a minute apart,
whereas in our study the first presentation of words in the study phase and the presentation of old word-stems during scanning were separated by a much longer interval (~40 min). Because repetition suppression can be sensitive to lag (Henson et al., 2000 ), it may be that weaker
repetition suppression with longer lags is more sensitive to drug
influences. Indeed, Nissen et al. (1987) found that word fragment
completion was impaired by scopolamine when there was a 60 min delay
between study and test phase but not when the delay was 5 min (although
the authors attributed these lag effects to an influence of explicit memory).
The extrastriate region, and its extension into inferior temporal
cortex, is an area that shows robust repetition suppression in
word-stem completion paradigms (Schacter and Buckner, 1998 ). It has
been argued that repetition suppression in this area is independent of
stimulus modality, because it is seen with visual and auditory
word-stem completion tasks and thus reflects processes beyond mere
perceptual facilitation (Badgaiyan et al., 1999 ; Buckner et al., 2000 ).
Lorazepam is known to impair perceptual processes (Wagemans et al.,
1998 ), and its behavioral effects on priming have often been
argued to be purely of perceptual nature (Giersch et al., 1995 ). The
present lack of repetition suppression in a putative "amodal" left
extrastriate region suggests impairments beyond a pure perceptual level
of processing (e.g., at a lexical level; Richardson-Klavehn and
Gardiner, 1998 ). The action of lorazepam on such an amodal level
of processing is consistent with previous data showing that lorazepam
impairs both visual and auditory word-stem completion (Vidailhet et
al., 1999 ). The proposal that behavioral deficits produced by both
drugs reflect influences beyond the perceptual level is further
supported by their effects in frontal areas.
Previous neuroimaging studies have also reported repetition suppression
in left inferior frontal cortex with repeated semantic word
classification, repetitive word generation, and word-stem completion
tasks (Demb et al., 1995 ; Thompson-Schill et al., 1999 ; Buckner et al.,
2000 ). This phenomenon could reflect increased efficiency of access,
retrieval, or selection of semantic information. An attenuation of
repetition suppression in frontal areas with both drugs suggests that
subjects treated with lorazepam and scopolamine might not benefit from
previous semantic processing.
Even if differential effects of lorazepam and scopolamine are weak when
compared with each other, trends in our data suggest a need to
investigate possible differential modulation of neuronal responses by
GABAergic and cholinergic systems. Although both drugs impaired
repetition suppression in critical brain areas, there were subtle
differences in the drugs' action when compared with placebo. Lorazepam
reduced activation to new word-stems in all three brain areas, a result
that suggests that lorazepam attenuated responses to words in the study
phase, which were all novel. Although the task during study phase was
different from test, such a conjecture would be consistent with
psychopharmacological evidence, that lorazepam impairs word-stem
completion when it is given before, but not after, a study phase
(Vidailhet et al., 1994 ). In other words, lorazepam may affect initial
processing of stimuli (e.g., at a lexical level; Richardson-Klavehn and
Gardiner, 1998 ) and the associated neuronal responses in left
extrastriate and frontal regions. However, whether insufficient
activation with initial stimulus presentation after lorazepam also
reduces the magnitude of neuronal activations during subsequent
processing of these stimuli (e.g., activations to old word-stems) needs
further investigation.
Scopolamine, on the other hand increased activations to old word-stems,
at least in left extrastriate cortex. Response enhancements with
repeated stimulus presentations have previously been found in right
fusiform cortex for repetition of unfamiliar or degraded faces and
might reflect additional processing (George et al., 1999 ; Henson et
al., 2000 ). Behaviorally, repetition of unfamiliar faces induced less
repetition priming, as measured by reaction times, than repetition of
familiar faces (Henson et al., 2000 ). Repetition enhancements to old
words in a word-stem completion paradigm have been observed in right
extrastriate regions of Alzheimer's patients, who show behaviorally
similar priming impairments as our scopolamine subjects (Backman et
al., 2000 ). Thus, repetition-related response enhancements instead of
decreases in extrastriate areas are also observed in other conditions
that show reduced repetition priming.
Conclusion
We demonstrate that GABAergic and cholinergic systems influence
the behavioral expression of word-stem completion priming. This
behavioral change was associated with an impairment of repetition suppression in left extrastriate, left middle frontal, and left inferior frontal cortices, thus pointing to a locus of the drugs' cerebral action in word-stem completion paradigms.
At a broader level the present study is a first step to investigate the
pharmacological basis of repetition suppression and behavioral priming
in humans. Although further studies are needed to understand the
mechanistic basis of cholinergic and GABAergic modulation of repetition
priming, the present data nevertheless show an important concurrence in
behavioral impairments of repetition priming with regionally specific
impairments in repetition related hemodynamic response reductions.
These findings indicate that the neurochemical modulation of human
learning and memory are now amenable to investigation in
vivo.
 |
FOOTNOTES |
Received April 26, 2001; revised June 19, 2001; accepted June 19, 2001.
This work was supported by program grants from the Wellcome Trust to
R.J.D. and K.J.F., a Wellcome Trust Fellowship to R.N.A.H., and a
research grant from the German Research Foundation (Deutsche Forschungsgemeinschaft) to C.M.T. We thank the radiographers at the
Functional Imaging Lab for help with fMRI scanning and medical colleagues for help with injections. Stimuli for the word-stem completion task were kindly provided by R. D. Badgaiyan. Thanks to
Richard Frackowiak for his helpful comments on an earlier version of
this manuscript.
Correspondence should be addressed to Christiane Thiel, Wellcome
Department of Cognitive Neurology, Institute of Neurology, 12 Queen
Square, London, WC1 3BG, UK. E-mail: cthiel{at}fil.ion.ucl.ac.uk.
 |
REFERENCES |
-
Backman L,
Almkvist O,
Nyberg L,
Andersson J
(2000)
Functional changes in brain activity during priming in Alzheimer's disease.
J Cogn Neurosci
12:134-141[Abstract/Free Full Text].
-
Badgaiyan RD,
Schacter DL,
Alpert NM
(1999)
Auditory priming within and across modalities: evidence from positron emission tomography.
J Cogn Neurosci
11:337-348[Abstract/Free Full Text].
-
Blokland A
(1996)
Acetylcholine: a neurotransmitter for learning and memory?
Brain Res Rev
21:285-300.
-
Bond A,
Lader M
(1974)
The use of analogue scales in rating subjective feelings.
Br J Med Psychol
47:211-218[ISI].
-
Brocher S,
Artola A,
Singer W
(1992)
Agonists of cholinergic and noradrenergic receptors facilitate synergistically the induction of long-term potentiation in slices of rat visual cortex.
Brain Res
573:27-36[ISI][Medline].
-
Buckner RL,
Goodman J,
Burock M,
Rotte M,
Koutstaal W,
Schacter D,
Rosen B,
Dale AM
(1998)
Functional-anatomic correlates of object priming in humans revealed by rapid presentation event-related fMRI.
Neuron
20:285-296[ISI][Medline].
-
Buckner RL,
Koutstaal W,
Schacter DL,
Rosen BR
(2000)
Functional MRI evidence for a role of frontal and inferior temporal cortex in amodal components of priming.
Brain
123:620-640[Abstract/Free Full Text].
-
Buffett-Jerrott SE,
Stewart SH,
Teehan MD
(1998)
A further examination of the time-dependent effects of oxazepam and lorazepam on implicit and explicit memory.
Psychopharmacology
138:344-353[Medline].
-
Caine ED,
Weingartner H,
Ludlow CL,
Cudahy EA,
Wehry S
(1981)
Qualitative analysis of scopolamine-induced amnesia.
Psychopharmacology
74:74-80[Medline].
-
Curran HV,
Pooviboonsuk P,
Dalton JA,
Lader MH
(1991a)
Differentiating the effects of centrally acting drugs on arousal and memory: an event-related potential study of scopolamine, lorazepam and diphenhydramine.
Psychopharmacology
135:27-36.
-
Curran HV,
Schifano F,
Lader MH
(1991b)
Models for memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood.
Psychopharmacology
103:83-90[Medline].
-
Danion JM,
Zimmermann MA,
Willard-Schroeder D,
Grange D,
Welsch M,
Imbs JL,
Singer L
(1990)
Effects of scopolamine, trimipramine and diazepam on explicit memory and repetition priming in healthy volunteers.
Psychopharmacology
102:422-424[Medline].
-
Demb JB,
Desmond JE,
Wagner AD,
Vaidya CJ,
Glover GH,
Gabrieli JD
(1995)
Semantic encoding and retrieval in the left inferior prefrontal cortex: a functional MRI study of task difficulty and process specificity.
J Neurosci
15:5870-5878[Abstract].
-
Desimone R
(1996)
Neural mechanisms for visual memory and their role in attention.
Proc Natl Acad Sci USA
93:13494-13499[Abstract/Free Full Text].
-
Ebert U,
Siepmann M,
Oertel R,
Wesnes KA,
Kirch W
(1998)
Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration.
J Clin Pharmacol
38:720-726[Abstract].
-
Frey KA,
Koeppe RA,
Mulholland GK,
Jewett D,
Hichwa R,
Ehrenkaufer RL,
Carey JE,
Wieland DM,
Kuhl DE,
Agranoff BW
(1992)
In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography.
J Cereb Blood Flow Metab
12:147-154[Medline].
-
Friston KJ,
Holmes AP,
Worsley KP,
Poline J-B,
Frith CD,
Frackowiak RSJ
(1995)
Statistical parametric maps in functional imaging: a general linear approach.
Hum Brain Mapp
2:189-210.
-
Frith CD,
Richardson JT,
Samuel M,
Crow TJ,
McKenna PJ
(1984)
The effects of intravenous diazepam and hyoscine upon human memory.
Q J Exp Psychol [A]
36:133-144[Medline].
-
Furey ML,
Pietrini P,
Haxby JV
(2000)
Cholinergic enhancement and increased selectivity of perceptual processing during working memory.
Science
290:2315-2319[Abstract/Free Full Text].
-
George N,
Dolan RJ,
Fink GR,
Baylis GC,
Russell C,
Driver J
(1999)
Contrast polarity and face recognition in the human fusiform gyrus.
Nat Neurosci
2:574-580[ISI][Medline].
-
Giersch A,
Boucart M,
Danion JM,
Vidailhet P,
Legrand F
(1995)
Effects of lorazepam on perceptual integration of visual forms in healthy volunteers.
Psychopharmacology
119:105-114[Medline].
-
Graf P,
Mandler G
(1984)
Activation makes words more accessible, but not necessarily more retrievable.
J Verb Learn Verb Behav
23:553-568.
-
Greenblatt DJ
(1981)
Clinical pharmacokinetics of oxazepam and lorazepam.
Clin Pharmacokinet
6:89-105[ISI][Medline].
-
Henson R,
Shallice T,
Dolan R
(2000)
Neuroimaging evidence for dissociable forms of repetition priming.
Science
287:1269-1272[Abstract/Free Full Text].
-
Josephs O,
Henson RN
(1999)
Event-related functional magnetic resonance imaging: modelling, inference and optimization.
Philos Trans R Soc Lond B Biol Sci
354:1215-1228[ISI][Medline].
-
Knopman D
(1991)
Unaware learning versus preserved learning in pharmacologic amnesia: similarities and differences.
J Exp Psychol Learn Mem Cogn
17:1017-1029[ISI][Medline].
-
Legrand F,
Vidailhet P,
Danion JM,
Grange D,
Giersch A,
van der Linden M,
Imbs JL
(1995)
Time course of the effects of diazepam and lorazepam on perceptual priming and explicit memory.
Psychopharmacology
118:475-479[Medline].
-
Li L,
Miller EK,
Desimone R
(1993)
The representation of stimulus familiarity in anterior inferior temporal cortex.
J Neurophysiol
69:1918-1929[Abstract/Free Full Text].
-
Martinez R,
Molchan SE,
Lawlor BA,
Thompson K,
Martinson H,
Latham G,
Weingartner H,
Sunderland T
(1997)
Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans.
Biol Psychiatry
41:50-57[Medline].
-
Miller EK,
Desimone R
(1993)
Scopolamine affects short-term memory but not inferior temporal neurons.
NeuroReport
4:81-84[ISI][Medline].
-
Nissen MJ,
Knopman DS,
Schacter DL
(1987)
Neurochemical dissociation of memory systems.
Neurology
37:789-794[Abstract/Free Full Text].
-
Nuotto E
(1983)
Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man.
Eur J Clin Pharmacol
24:603-609[ISI][Medline].
-
Putcha L,
Cintron NM,
Tsui J,
Vanderploeg JM,
Kramer WG
(1989)
Pharmacokinetics and oral bioavailability of scopolamine in normal subjects.
Pharmacol Res
6:481-485.
-
Rasmusson DD
(2000)
The role of acetylcholine in cortical synaptic plasticity.
Behav Brain Res
115:205-218[ISI][Medline].
-
Richardson-Klavehn A,
Gardiner JM
(1998)
Depth-of-processing effects on priming in stem completion: tests of the voluntary-contamination, conceptual-processing, and lexical-processing hypotheses.
J Exp Psychol Learn Mem Cogn
24:593-609[Medline].
-
Rusted JM,
Warburton DM
(1988)
The effects of scopolamine on working memory in healthy young volunteers.
Psychopharmacology
96:145-152[Medline].
-
Safer DJ,
Allen RP
(1971)
The central effects of scopolamine in man.
Biol Psychiatry
3:347-355[ISI][Medline].
-
Sannita WG,
Fioretto M,
Maggi L,
Rosadini G
(1987)
Effects of scopolamine parenteral administration on the electroretinogram, visual evoked potentials, and quantitative electroencephalogram of healthy volunteers.
Doc Ophthalmol
67:379-388[Medline].
-
Schacter DL,
Buckner RL
(1998)
Priming and the brain.
Neuron
20:185-195[ISI][Medline].
-
Schifano F,
Curran HV
(1994)
Pharmacological models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on word valence ratings, priming and recall.
Psychopharmacology
115:430-434[Medline].
-
Squire LR,
Ojemann JG,
Miezin FM,
Petersen SE,
Videen TO,
Raichle ME
(1992)
Activation of the hippocampus in normal humans: a functional anatomical study of memory.
Proc Natl Acad Sci USA
89:1837-1841[Abstract/Free Full Text].
-
Sunderland T,
Tariot PN,
Cohen RM,
Weingartner H,
Mueller III EA,
Murphy DL
(1987)
Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.
Arch Gen Psychiatry
44:418-426[Abstract].
-
Thompson-Schill SL,
D'Esposito M,
Kan IP
(1999)
Effects of repetition and competition on activity in left prefrontal cortex during word generation.
Neuron
23:513-522[ISI][Medline].
-
Tsukada H,
Kakiuchi T,
Ando I,
Shizuno H,
Nakanishi S,
Ouchi Y
(1997)
Regulation of cerebral blood flow response to somatosensory stimulation through the cholinergic system: a positron emission tomography study in unanesthetized monkeys.
Brain Res
749:10-17[ISI][Medline].
-
Vidailhet P,
Danion JM,
Kauffmann-Muller F,
Grange D,
Giersch A,
van der Linden M,
Imbs JL
(1994)
Lorazepam and diazepam effects on memory acquisition in priming tasks.
Psychopharmacology
115:397-406[Medline].
-
Vidailhet P,
Danion JM,
Chemin C,
Kazes M
(1999)
Lorazepam impairs both visual and auditory perceptual priming.
Psychopharmacology
147:266-273[Medline].
-
Vitiello B,
Martin A,
Hill J,
Mack C,
Molchan S,
Martinez R,
Murphy DL,
Sunderland T
(1997)
Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans.
Neuropsychopharmacology
16:15-24[ISI][Medline].
-
Wagemans J,
Notebaert W,
Boucart M
(1998)
Lorazepam but not diazepam impairs identification of pictures on the basis of specific contour fragments.
Psychopharmacology
138:326-333[Medline].
-
Wagner AD,
Koutstaal W,
Maril A,
Schacter DL,
Buckner RL
(2000)
Task-specific repetition priming in left inferior prefrontal cortex.
Cereb Cortex
10:1176-1184[Abstract/Free Full Text].
-
Weinberger NM
(1998)
Physiological memory in primary auditory cortex: characteristics and mechanisms.
Neurobiol Learn Mem
70:226-251[ISI][Medline].
-
Wiggs CL,
Martin A
(1998)
Properties and mechanisms of perceptual priming.
Curr Opin Neurobiol
8:227-233[ISI][Medline].
Copyright © 2001 Society for Neuroscience 0270-6474/01/21176846-07$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
N. Lange
What can modern statistics offer imaging neuroscience?
Statistical Methods in Medical Research,
October 1, 2003;
12(5):
447 - 469.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
E. L. Grigorenko
The first candidate gene for dyslexia: Turning the page of a new chapter of research
PNAS,
September 30, 2003;
100(20):
11190 - 11192.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Bentley, P. Vuilleumier, C. M. Thiel, J. Driver, and R. J. Dolan
Effects of Attention and Emotion on Repetition Priming and Their Modulation by Cholinergic Enhancement
J Neurophysiol,
August 1, 2003;
90(2):
1171 - 1181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bullmore, J. Suckling, F. Zelaya, C. Long, G. Honey, L. Reed, C. Routledge, V. Ng, P. Fletcher, J. Brown, et al.
Practice and Difficulty Evoke Anatomically and Pharmacologically Dissociable Brain Activation Dynamics
Cereb Cortex,
February 1, 2003;
13(2):
144 - 154.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Donchin, L. Sawaki, G. Madupu, L. G. Cohen, and R. Shadmehr
Mechanisms Influencing Acquisition and Recall of Motor Memories
J Neurophysiol,
October 1, 2002;
88(4):
2114 - 2123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sperling, D. Greve, A. Dale, R. Killiany, J. Holmes, H. D. Rosas, A. Cocchiarella, P. Firth, B. Rosen, S. Lake, et al.
Functional MRI detection of pharmacologically induced memory impairment
PNAS,
December 21, 2001;
(2001)
12467899.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sperling, D. Greve, A. Dale, R. Killiany, J. Holmes, H. D. Rosas, A. Cocchiarella, P. Firth, B. Rosen, S. Lake, et al.
Functional MRI detection of pharmacologically induced memory impairment
PNAS,
January 8, 2002;
99(1):
455 - 460.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|